KR20010088832A - 통증 및 불안증 치료용 ｍＧｌｕＲ5 길항제 - Google Patents

통증 및 불안증 치료용 ｍＧｌｕＲ5 길항제 Download PDF

Info

Publication number
KR20010088832A
KR20010088832A KR1020017004152A KR20017004152A KR20010088832A KR 20010088832 A KR20010088832 A KR 20010088832A KR 1020017004152 A KR1020017004152 A KR 1020017004152A KR 20017004152 A KR20017004152 A KR 20017004152A KR 20010088832 A KR20010088832 A KR 20010088832A
Authority
KR
South Korea
Prior art keywords
mglur
antagonist
pain
mglur5
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020017004152A
Other languages
English (en)
Korean (ko)
Inventor
한스 앨가이어
니콜라스 데이비드 코스포드
피터 조제프 플로르
파브리지오 가스파리니
콘라드 겐취
스테펜 디. 헤쓰
에드윈 칼 존슨
라이너 쿤
마크 트리클뱅크
라스즐로 얼번
마크 앤드류 바니
괴뉠 벨리셀레비
캐써린 월커
Original Assignee
한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터
노파르티스 아게
추후제출
시비아 뉴로사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20010088832(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터, 노파르티스 아게, 추후제출, 시비아 뉴로사이언시즈 인코포레이티드 filed Critical 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터
Publication of KR20010088832A publication Critical patent/KR20010088832A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020017004152A 1998-10-02 1999-09-30 통증 및 불안증 치료용 ｍＧｌｕＲ5 길항제 Ceased KR20010088832A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9821503.1 1998-10-02
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
US09/220,813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number Publication Date
KR20010088832A true KR20010088832A (ko) 2001-09-28

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017004152A Ceased KR20010088832A (ko) 1998-10-02 1999-09-30 통증 및 불안증 치료용 ｍＧｌｕＲ5 길항제

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
KR100545906B1 (ko) * 2000-12-22 2006-01-26 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
RS60199B1 (sr) 2015-06-03 2020-06-30 Hoffmann La Roche Derivati etinila
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68907095T2 (de) * 1988-03-21 1994-01-05 Boehringer Ingelheim Pharma Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
ID29095A (id) 2001-07-26
ES2213389T3 (es) 2004-08-16
AU6198499A (en) 2000-04-26
BR9914215A (pt) 2001-07-03
PT1117403E (pt) 2004-04-30
CN1187048C (zh) 2005-02-02
WO2000020001A1 (en) 2000-04-13
NO20011440D0 (no) 2001-03-21
CA2345137A1 (en) 2000-04-13
DE69913548T2 (de) 2004-09-23
RU2232017C2 (ru) 2004-07-10
ATE255894T1 (de) 2003-12-15
EP1117403A1 (en) 2001-07-25
IL142047A0 (en) 2002-03-10
JP2002526408A (ja) 2002-08-20
NO20011440L (no) 2001-05-15
CN1321087A (zh) 2001-11-07
DK1117403T3 (da) 2004-04-13
SK4382001A3 (en) 2001-08-06
PL202906B1 (pl) 2009-08-31
NZ510743A (en) 2003-10-31
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
EP1117403B1 (en) 2003-12-10
AU765644B2 (en) 2003-09-25
HUP0200553A3 (en) 2002-11-28
HUP0200553A2 (hu) 2002-07-29
PL346876A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
KR20010088832A (ko) 통증 및 불안증 치료용 ｍＧｌｕＲ5 길항제
KR100442675B1 (ko) 데스카르보에톡시로라타딘을이용한알레르기성비염과다른질병의치료방법과조성물
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
JP2020079312A (ja) 眼障害の治療のための組成物および方法
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
JP2002526408A5 (https=)
Lynch III et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
US20120289542A1 (en) Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
KR20020075797A (ko) 엔도텔린 유발성 질환 치료제
AU2008333220A1 (en) Mequitazine for treating or preventing pathologies involving histamine H4 receptors
WO2006128035A2 (en) Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
JP2021532188A (ja) μオピオイド受容体のアロステリックモジュレーター
US20130203789A1 (en) Novel Inhibitors of LYN Kinase and Methods Using Same
EP1804795A2 (en) Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20110251396A1 (en) Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
MX2007016594A (en) Thiazolopyrimidines for use in therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010331

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040908

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060106

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060403

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I